- Home
- FBIO vs ALGS Comparison
FBIO vs ALGS Comparison
Compare FBIO & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- ALGS
- Stock Information
- Founded
- FBIO 2006
- ALGS 2018
- Country
- FBIO United States
- ALGS United States
- Employees
- FBIO N/A
- ALGS N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- ALGS Health Care
- Exchange
- FBIO Nasdaq
- ALGS Nasdaq
- Market Cap
- FBIO 49.1M
- ALGS 50.4M
- IPO Year
- FBIO N/A
- ALGS 2020
- Fundamental
- Price
- FBIO $1.88
- ALGS $7.84
- Analyst Decision
- FBIO Strong Buy
- ALGS Strong Buy
- Analyst Count
- FBIO 2
- ALGS 1
- Target Price
- FBIO $21.00
- ALGS $70.00
- AVG Volume (30 Days)
- FBIO 233.4K
- ALGS 125.8K
- Earning Date
- FBIO 08-12-2025
- ALGS 08-05-2025
- Dividend Yield
- FBIO N/A
- ALGS N/A
- EPS Growth
- FBIO N/A
- ALGS N/A
- EPS
- FBIO N/A
- ALGS N/A
- Revenue
- FBIO $57,784,000.00
- ALGS $3,270,000.00
- Revenue This Year
- FBIO $51.59
- ALGS N/A
- Revenue Next Year
- FBIO $44.74
- ALGS $51.55
- P/E Ratio
- FBIO N/A
- ALGS N/A
- Revenue Growth
- FBIO N/A
- ALGS N/A
- 52 Week Low
- FBIO $1.33
- ALGS $3.76
- 52 Week High
- FBIO $2.89
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- FBIO 53.63
- ALGS 57.02
- Support Level
- FBIO $1.76
- ALGS $6.82
- Resistance Level
- FBIO $1.89
- ALGS $8.66
- Average True Range (ATR)
- FBIO 0.10
- ALGS 0.76
- MACD
- FBIO -0.01
- ALGS -0.06
- Stochastic Oscillator
- FBIO 75.00
- ALGS 55.49
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.